~~<i id='95EFFF343A'><strike id='95EFFF343A'><tt id='95EFFF343A'><pre id='95EFFF343A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

focus

author：focus 2025-09-28 00:49:00 - browse：92251

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Scientists inch closer to single

focus

explore

focus

hotspot

explore

knowledge

TheU.S.PreventiveServicesTaskForcewilldiscussrecommendingCovid-19screening,thefirststepinrequiringin

WSS

What to expect as Trump is arraigned on his Jan 6. indictment

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Top private equity targets in 2023: cardiology, clinical trials, lasers

explore

focus

focus

Jerome Adams on the need for new antivirals for Covid

Devoted Health’s losses in Medicare Advantage persist

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Bernie brings in new pharma CEOs to talk drug prices

Hepatitis C has a cure — but many Americans still lack access to it

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Cancer drug shortages should be causing more outrage

What to expect as Trump is arraigned on his Jan 6. indictment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why CTE doesn’t keep Americans from enjoying the Super Bowl

explore

New safety details link Apellis eye drug to rare cases of blindness

Sage hopes for a blockbuster in antidepressant now before FDA

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

National panel will explore requiring free Covid tests

Micronoma's microbiome cancer diagnostic approach under fire

Johnson & Johnson sued for allegedly overpaying for workers' drugs

focus

hotspot

explore

knowledge